Adjuvant and transmucosal vaccine
AssigneeJuntendo Educational Foundation
InventorsHiraku SASAKI, Yoshio SUZUKI, Hiroki ISHIKAWA
Life of this patent
Estimating the term…
Abstract
An adjuvant and a transmucosal vaccine may have a high ability of inducing, through transmucosal administration, secretory IgA in addition to serum IgA and IgG. Such an adjuvant may contain, as an active ingredient, one or more polypeptides selected from (1) a polypeptide having one or two amino acid sequences shown in at least SEQ ID NO: 1, and (2) a polypeptide having 93% or more identity to the amino acid sequence.
Claims23
An adjuvant, comprising, as an active ingredient:
- a polypeptide consisting of an amino acid sequence show in SEQ ID NO:
- 1, 4, or 10.
An adjuvant, comprising, as an active ingredient:
- a polypeptide consisting of an amino acid sequence shown in SEQ ID NO:
- 2, 3, 5, 6, 7, 8, 9, 11, 12, 13, 14, or 15.
An adjuvant, comprising, as an active ingredient:
- a polypeptide consisting of an amino acid sequence shown in SEQ ID NO:
- 5, 6, 7, 8, 9, 11, 12, 13, 14, or 15.
4-8. (canceled)
15-17. (canceled)
Dependencies are inferred from the claim text.